Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 112Terminated 36Unknown 20Active not recruiting 8Withdrawn 5Recruiting 3Not yet recruiting 3Approved for marketing 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 5Kidney Neoplasms 3Neoplasm Metastasis 1Glioblastoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 19Docetaxel 16Magnetic Resonance Spectroscopy 14Prednisone 13Radiotherapy 11bicalutamide 10Leuprolide 10Abiraterone Acetate 9Radiosurgery 8Cyclophosphamide 8Biopsy 8avelumab 7atezolizumab 6Specimen Handling 6Interleukin-2 6Gemcitabine 6Bevacizumab 6Androgen Antagonists 6tremelimumab 5gallium 68 PSMA-11 5apalutamide 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Sunitinib 5Paclitaxel 5Metformin 5Injections 5Goserelin 5Cisplatin 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Withdrawn × Sunitinib × Genitourinary × Clear all
NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03323710 2019-01-09

Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

Military Institute od Medicine National Research Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00556205 2016-03-24

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT01070186 2012-07-31

Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡